Kamada Ltd. is an Israel-based biopharmaceutical company, which develops, produces and markets therapeutics, based on chromatographic purification technology. It offers bio-therapeutics for human use, such as specialty proteins, specific immunoglobulins, and other prescription medicines. The Company's product line includes intravenous AAT for chronic replacement therapy in individuals with congenital alpha-1 antitrypsin deficiency; KamRAB for prophylaxis of rabies infection; KamRho-D IM for prophylaxis of Rh hemolytic disease of the newborn; KamRho-D IV for treatment of immune thrombocytopenic purpura; and IVIG, a replacement therapy in primary and secondary immune therapy. Its product line also comprises Protosol to reduce blood loss in patients undergoing cardiac surgery; Heparin sodium injection for coagulation inhibition and prophylaxis of thromboembolic diseases and Heparin Lock Flush to maintain potency of intravenous injection device among other.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biopharmaceuticals
- Sub-Industry: N/A
- Symbol: NASDAQ:KMDA
- CUSIP: N/A
- Web: www.kamada.com
Capitalization:- Market Cap: $207.75 million
- Outstanding Shares: 36,154,000
Average Prices:- 50 Day Moving Avg: $6.71
- 200 Day Moving Avg: $6.78
- 52 Week Range: $3.85 - $8.61
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: 17.50
- P/E Growth: 16.11
Sales & Book Value:- Annual Revenue: $74.35 million
- Price / Sales: 2.72
- Book Value: $1.75 per share
- Price / Book: 3.20
Profitability:- EBIDTA: ($3,660,000.00)
- Net Margins: -11.31%
- Return on Equity: -12.55%
- Return on Assets: -8.72%
Debt:- Debt-to-Equity Ratio: 0.02%
- Current Ratio: 2.82%
- Quick Ratio: 1.71%
Misc:- Average Volume: 66,694 shs.
- Beta: 1.09
- Short Ratio: 1.47
Frequently Asked Questions for Kamada (NASDAQ:KMDA)
What is Kamada's stock symbol?
Kamada trades on the NASDAQ under the ticker symbol "KMDA."
How were Kamada's earnings last quarter?
Kamada Ltd. (NASDAQ:KMDA) issued its quarterly earnings data on Tuesday, May, 16th. The company reported ($0.11) earnings per share for the quarter, missing the consensus estimate of ($0.03) by $0.08. The business earned $11.65 million during the quarter, compared to analysts' expectations of $20.82 million. Kamada had a negative return on equity of 12.55% and a negative net margin of 11.31%. View Kamada's Earnings History.
Where is Kamada's stock going? Where will Kamada's stock price be in 2017?
2 brokerages have issued 1 year price objectives for Kamada's stock. Their forecasts range from $9.00 to $10.00. On average, they anticipate Kamada's stock price to reach $9.50 in the next twelve months. View Analyst Ratings for Kamada.
Who are some of Kamada's key competitors?
Some companies that are related to Kamada include Sinovac Biotech (SVA), Syndax Pharmaceuticals (SNDX), Peregrine Pharmaceuticals (PPHM), Fortress Biotech (FBIO), Mereo BioPharma Group PLC (MPH), MediWound (MDWD), Kadmon Holdings (KDMN), Cardiome Pharma Corporation (CRME), VIVUS (VVUS), Strongbridge Biopharma PLC (SBBP), Vericel Corporation (VCEL), Alimera Sciences (ALIM), KalVista Pharmaceuticals (KALV), Tokai Pharmaceuticals (NVUS), Chiasma (CHMA), Cesca Therapeutics (KOOL), Mirna Therapeutics (MIRN) and Ocera Therapeutics (OCRX).
Who are Kamada's key executives?
Kamada's management team includes the folowing people:
- Leon Yehuda Recanati, Chairman of the Board
- Amir London, Chief Executive Officer
- Gil Efron, Deputy Chief Executive Officer, Chief Financial Officer
- David Tsur, Deputy Chairman of the Board
- Ruth Wolfson, Senior Vice President - Scientific Affairs
- Barak Bashari, Vice President - Operations
- Shani Dotan, Vice President - Human Resources
- Yael Brenner, Vice President - Quality
- Orit Pinchuk, Vice President - Regulatory Affairs and Quality R&D
- Eran Schenker, Vice President - Medical Director
How do I buy Kamada stock?
Shares of Kamada can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Kamada's stock price today?
One share of Kamada stock can currently be purchased for approximately $5.60.
MarketBeat Community Rating for Kamada (NASDAQ KMDA)MarketBeat's community ratings are surveys of what our community members think about Kamada and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Kamada (NASDAQ:KMDA) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 2 Buy Ratings |
| Consensus Rating: | Buy (Score: 3.00) |
| Consensus Price Target: | $9.50 (69.64% upside) |
Analysts' Ratings History for Kamada (NASDAQ:KMDA)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 5/17/2017 | Jefferies Group LLC | Reiterated Rating | Buy | $9.00 | High |  |
| 2/7/2017 | HC Wainwright | Set Price Target | Buy | $10.00 | N/A | |
(Data available from 7/20/2015 forward)
Earnings History for Kamada (NASDAQ:KMDA)Earnings History by Quarter for Kamada (NASDAQ KMDA)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 5/16/2017 | 3/31/2017 | ($0.03) | ($0.11) | $20.82 million | $11.65 million | View | N/A | |
| 2/6/2017 | 12/31/2016 | ($0.04) | ($0.05) | $27.74 million | $24.26 million | View | Listen | |
| 11/10/2016 | 9/30/2016 | ($0.04) | ($0.03) | $20.32 million | $19.37 million | View | N/A | |
| 8/2/2016 | Q216 | ($0.04) | ($0.04) | $18.50 million | $19.10 million | View | N/A | |
| 5/9/2016 | Q1 2016 | ($0.06) | ($0.06) | $15.10 million | $14.80 million | View | N/A | |
| 2/2/2016 | Q415 | ($0.09) | $0.03 | $27.10 million | $25.90 million | View | N/A | |
| 11/10/2015 | Q315 | ($0.04) | ($0.13) | $18.67 million | $16.10 million | View | Listen | |
| 7/30/2015 | Q215 | ($0.03) | ($0.06) | $21.82 million | $19.20 million | View | Listen | |
| 5/12/2015 | Q115 | ($0.05) | ($0.15) | $16.12 million | $9.00 million | View | Listen | |
| 2/11/2015 | Q4 | $0.01 | $0.05 | $24.53 million | $25.79 million | View | N/A | |
| 11/12/2014 | Q314 | ($0.04) | ($0.09) | $19.00 million | $17.20 million | View | N/A | |
| 8/14/2014 | Q214 | ($0.02) | ($0.23) | $17.17 million | $15.80 million | View | N/A | |
| 5/8/2014 | Q114 | ($0.03) | ($0.09) | $15.97 million | $13.20 million | View | N/A | |
| 2/5/2014 | Q413 | $0.05 | $0.04 | $25.22 million | $24.40 million | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Kamada (NASDAQ:KMDA)2017 EPS Consensus Estimate: $0.19
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 1 | $0.00 | $0.00 | $0.00 |
| Q2 2017 | 1 | $0.10 | $0.10 | $0.10 |
| Q3 2017 | 1 | $0.03 | $0.03 | $0.03 |
| Q4 2017 | 1 | $0.06 | $0.06 | $0.06 |
(Data provided by Zacks Investment Research)
Dividend History for Kamada (NASDAQ:KMDA)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for Kamada (NASDAQ:KMDA)
No insider trades for this company have been tracked by MarketBeat.com
Headline Trends for Kamada (NASDAQ:KMDA)
Latest Headlines for Kamada (NASDAQ:KMDA)
| Source: |
|
| Date | Headline |
|---|
 | ETFs with exposure to Kamada Ltd. : July 7, 2017
finance.yahoo.com - July 8 at 12:04 PM |
 | $32.90 Million in Sales Expected for Kamada Ltd. (NASDAQ:KMDA) This Quarter
www.americanbankingnews.com - July 6 at 10:08 AM |
| Zacks: Analysts Anticipate Kamada Ltd. (NASDAQ:KMDA) Will Post Earnings of $0.12 Per Share
www.americanbankingnews.com - July 4 at 6:24 PM |
| Kamada Withdraws Inhaled AAT Marketing Application in EU
finance.yahoo.com - June 23 at 6:35 PM |
 | Kamada (KMDA) Withdrawal of European MAA for Inhaled Alpha-1 Antitrypsin for Treatment of Alpha-1 Antitrypsin Deficiency Disease
www.streetinsider.com - June 23 at 7:34 AM |
 | Kamada Ltd. (KMDA) Is Sinking After European Application Withdrawn
www.nasdaq.com - June 23 at 7:34 AM |
 | Kamada Ltd. (KMDA) Sank To Nearly A 5-Month Low
www.rttnews.com - June 23 at 7:34 AM |
| Kamada Announces Withdrawal of European Marketing Authorization Application for Inhaled Alpha-1 Antitrypsin for Treatment of Alpha-1 Antitrypsin Deficiency Disease
finance.yahoo.com - June 22 at 12:44 PM |
| ETFs with exposure to Kamada Ltd. : June 16, 2017
finance.yahoo.com - June 16 at 7:04 PM |
| Kamada Ltd. :KMDA-US: Earnings Analysis: Q1, 2017 By the Numbers : June 14, 2017
finance.yahoo.com - June 14 at 10:58 AM |
| Kamada (KMDA) Receives Additional Milestone Payment Under GLASSIA Agreement with Shire
www.streetinsider.com - June 13 at 8:36 AM |
| Kamada Receives Additional Milestone Payment Under GLASSIA® Exclusive Supply and Distribution Agreement with Shire
finance.yahoo.com - June 12 at 3:21 PM |
| $32.90 Million in Sales Expected for Kamada Ltd (KMDA) This Quarter
www.americanbankingnews.com - June 10 at 8:22 AM |
| $0.12 Earnings Per Share Expected for Kamada Ltd (KMDA) This Quarter
www.americanbankingnews.com - June 8 at 4:30 PM |
| Kamada Provides Update on Clinical Program for Alpha-1 Antitrypsin IV for Treatment of Graft-Versus-Host Disease
finance.yahoo.com - June 7 at 9:39 AM |
| Kamada Announces Appointment of Michal Stein, M.D., as Vice President and Medical Director
finance.yahoo.com - June 5 at 9:58 AM |
| Kamada Presents Updated Data from Phase 2 Clinical Trial of Inhaled Alpha-1-Antitrypsin for Treatment of Alpha-1 Antitrypsin Deficiency at 2017 American Thoracic Society International Conference
finance.yahoo.com - May 24 at 11:14 AM |
| Kamada Ltd (KMDA) to Post Q2 2017 Earnings of $0.10 Per Share, Jefferies Group Forecasts
www.americanbankingnews.com - May 19 at 7:16 AM |
| Short Interest in Kamada Ltd (KMDA) Decreases By 9.0%
www.americanbankingnews.com - May 18 at 4:22 PM |
| Kamada Ltd (KMDA) Downgraded to "Strong Sell" at Zacks Investment Research
www.americanbankingnews.com - May 18 at 12:30 PM |
| FY2017 EPS Estimates for Kamada Ltd Reduced by Jefferies Group (KMDA)
www.americanbankingnews.com - May 18 at 10:38 AM |
| Kamada (KMDA) Posts Q1 Loss Wider than Expected, Sales Miss
finance.yahoo.com - May 17 at 6:10 PM |
| Kamada Ltd (KMDA) Earns Buy Rating from Jefferies Group LLC
www.americanbankingnews.com - May 17 at 11:34 AM |
| Kamada Ltd (KMDA) Issues Earnings Results
www.americanbankingnews.com - May 17 at 10:03 AM |
| Kamada Reports 2017 First Quarter Financial Results
finance.yahoo.com - May 16 at 10:49 AM |
| Kamada reports 1Q loss
finance.yahoo.com - May 16 at 10:49 AM |
| Investor Network: Kamada Ltd to Host Earnings Call
finance.yahoo.com - May 16 at 10:49 AM |
| Analysts Anticipate Kamada Ltd (KMDA) Will Post Quarterly Sales of $20.82 Million
www.americanbankingnews.com - May 14 at 9:24 AM |
| Kamada to Host First Quarter 2017 Financial Results Conference Call on May 16
finance.yahoo.com - May 8 at 9:26 AM |
| Kamada (KMDA) Receives News Sentiment Rating of 0.35
www.americanbankingnews.com - May 3 at 1:00 AM |
| Kamada (KMDA) Receiving Somewhat Favorable Media Coverage, Analysis Shows
www.americanbankingnews.com - April 28 at 12:14 AM |
| Kamada (KMDA) Receives Media Impact Score of -0.12
www.americanbankingnews.com - April 24 at 1:38 PM |
| Kamada Ltd (KMDA) Expected to Announce Quarterly Sales of $20.82 Million
www.americanbankingnews.com - April 23 at 8:16 AM |
| Kamada (KMDA) Receiving Positive Press Coverage, AlphaOne Reports
www.americanbankingnews.com - April 18 at 5:28 PM |
| Kamada (KMDA) Earns Media Impact Score of 0.40
www.americanbankingnews.com - April 13 at 3:16 PM |
| Kamada's (KMDA) "Buy" Rating Reiterated at Jefferies Group LLC
www.americanbankingnews.com - April 12 at 3:53 PM |
| KAMADA LTD Financials
finance.yahoo.com - March 7 at 5:56 PM |
| Kamada to Host R&D Day Focused on Graft versus Host Disease (GvHD)
finance.yahoo.com - March 2 at 6:24 PM |
| Kamada (KMDA) to Collaborate with MGH on Study Evaluating Benefit of Liquid Alpha-1 Antitrypsin on Liver ... - StreetInsider.com
www.streetinsider.com - February 22 at 6:22 PM |
| Kamada (KMDA) to Collaborate with MGH on Study Evaluating Benefit of Liquid Alpha-1 Antitrypsin on Liver Preservation Prior to Transplantation
www.streetinsider.com - February 22 at 12:25 PM |
 | Kamada Announces Collaboration with Massachusetts General Hospital for Proof of Concept Study Evaluating Benefit of Liquid Alpha-1 Antitrypsin on Liver Preservation Prior to Transplantation
us.rd.yahoo.com - February 22 at 12:25 PM |
| 6:33 am Kamada announces a collaboration w/ Massachusetts General Hospital to conduct a study evaluating the potential benefit of its Liquid Alpha-1 Antitrypsin on liver preservation
us.rd.yahoo.com - February 22 at 12:25 PM |
| Kamada Announces Appointment of Biopharmaceutical Industry Veteran, Gwen Melincoff, to its Board of Directors
finance.yahoo.com - February 8 at 6:56 PM |
 | Kamada Reports Financial Results for the Fourth Quarter and Full-Year 2016
globenewswire.com - February 6 at 10:21 AM |
| Kamada to Host Fiscal Year 2016 Financial Results Conference Call on February 6
finance.yahoo.com - February 1 at 6:58 PM |
| Kamada Announces Positive Scientific Advice Response from the European ...
globenewswire.com - January 23 at 10:37 AM |
| Kamada (KMDA) Announces Positive Scientific Advice Response from CHMP on G1-AAT IV for aGvHD
www.streetinsider.com - January 23 at 10:37 AM |
| 6:30 am Kamada announces positive scientific advice response from the EMA focused on Alpha-1 Antitrypsin IV for treatment of acute graft-versus-host disease; co is in the process of reviewing CHMP guidance
finance.yahoo.com - January 23 at 10:37 AM |
| Kamada Announces Positive Scientific Advice Response from the European Medicines Agency Focused on Alpha-1 Antitrypsin IV for Treatment of Acute Graft-Versus-Host Disease
finance.yahoo.com - January 23 at 10:37 AM |
| Kamada (KMDA) Enters Recombinant Human Alpha 1 Antitrypsin Development Agreement
www.streetinsider.com - November 15 at 6:25 PM |
Kamada (KMDA) Chart for Thursday, July, 20, 2017
